Home
HelpTest ID MFCF Myeloma, FISH, Fixed Cells
Useful For
Aiding in the diagnosis of new cases of multiple myeloma
Identifying prognostic markers based on the abnormalities found
Reflex Tests
| Test ID | Reporting Name | Available Separately | Always Performed |
|---|---|---|---|
| _PBCT | Probe, +2 | No, (Bill Only) | No |
| _PADD | Probe, +1 | No, (Bill Only) | No |
| _PB02 | Probe, +2 | No, (Bill Only) | No |
| _PB03 | Probe, +3 | No, (Bill Only) | No |
| _IL25 | Interphases, <25 | No, (Bill Only) | No |
| _I099 | Interphases, 25-99 | No, (Bill Only) | No |
| _I300 | Interphases, ≥100 | No, (Bill Only) | No |
Testing Algorithm
This test includes a charge for application of the first probe set (2 FISH probes) and professional interpretation of results.
Additional charges will be incurred for all reflex probes performed. Analysis charges will be incurred based on the number of cells analyzed per probe set. If no cells are available for analysis, no analysis charges will be incurred.
This test is designed for diagnostic specimens.
Indicate if the entire panel is to be performed. If the patient is being tracked for known abnormalities, indicate which probes should be used.
Panel includes testing for the following abnormalities using the probes listed:
-13/13q-, RB1/LAMP1
t(11;14), CCND1/IGH
14q32 rearrangement, IGH
17p-, TP53/D17Z1
+3/+7, D3Z1/D7Z1
+9/+15, D9Z1/D15Z4
1q gain, TP73/CKS1B
8q24,1 rearrangement, MYC
When an IGH rearrangement is identified, reflex testing is performed to identify the translocation partner. Probes include identification of t(4;14)(p16.3;q32) FGFR3/IGH, t(14;16)(q32;q23) IGH/MAF, t(14;20)(q32;q12), IGH/MAFB or t(6;14)(p21;q32) CCND3/IGH.
Method Name
Fluorescence In Situ Hybridization (FISH)
Reporting Name
Myeloma, FISH, Fixed CellsSpecimen Type
Fixed Cell Pellet Bone MarrowProvide a reason for referral with each specimen. The laboratory will not reject testing if this information is not provided, but appropriate testing and interpretation may be compromised or delayed.
Provide a pathology report with each specimen.
Container/Tube: Sterile container
Specimen Volume: 1 fixed cell pellet
Collection Instructions: Place specimen in a sterile container with a 3:1 (or similar) fixative (methanol:glacial acetic acid).
Additional Information: Advise Express Mail or equivalent if not on courier service.
Forms: If not ordering electronically, complete, print, and send a Hematopathology/Cytogenetics Test Request Form (T726) with the specimen
(http://www.mayomedicallaboratories.com/it-mmfiles/hematopathology-request-form.pdf)
Specimen Stability Information
| Specimen Type | Temperature | Time |
|---|---|---|
| Fixed Cell Pellet Bone Marrow | Ambient (preferred) | |
| Refrigerated | ||
Clinical Information
Multiple myeloma is a hematologic neoplasm that generally originates in the bone marrow and develops from malignant plasma cells. There are 4 main categories of myeloma: asymptomatic myeloma, smoldering myeloma, indolent myeloma, and multiple myeloma. Asymptomatic myeloma patients have nonspecific symptoms that may be attributed to other diseases. Generalized bone pain, anemia, numbness or limb weakness, symptoms of hypercalcemia, and recurrent infections are all symptoms that may indicate myeloma. In smoldering myeloma there is a monoclonal protein spike, but it is stable. Indolent myeloma is a slowly progressing myeloma.
As myeloma progresses, the malignant plasma cells interfere with normal blood product formation in the bone marrow resulting in anemia and leukopenia. Myeloma also causes an overstimulation of osteoclasts, causing excessive breakdown of bone tissue without the normal corresponding bone formation. These bone lesions are seen in approximately 66% of myeloma patients. In advanced disease, bone loss may reach a degree where the patient suffers fractures easily.
Multiple myeloma is increasingly recognized as a disease characterized by marked cytogenetic, molecular, and proliferative heterogeneity. This heterogeneity is manifested clinically by varying degrees of disease aggressiveness. Multiple myeloma patients with more aggressive disease experience suboptimal responses to some therapeutic approaches; therefore, identifying these patients is critically important for selecting appropriate treatment options.
Reference Values
An interpretive report will be provided.
Cautions
This test is not approved by the US Food and Drug Administration and is best used as an adjunct to existing clinical and pathologic information.
Day(s) Performed
Samples processed Monday through Sunday. Results reported Monday through Friday, 8 a.m.-5 p.m. CST.
Report Available
7 daysPerforming Laboratory
Mayo Medical Laboratories in Rochester
Test Classification
This test was developed using an analyte specific reagent. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.CPT Code Information
88271x2, 88291 – DNA probe, each (first probe set), Interpretation and report
88271x2 – DNA probe, each; each additional probe set (if appropriate)
88271x1 – DNA probe, each; coverage for sets containing 3 probes (if appropriate)
88271x2 – DNA probe, each; coverage for sets containing 4 probes (if appropriate)
88271x3 – DNA probe, each; coverage for sets containing 5 probes (if appropriate)
88274 w/modifier 52 – Interphase in situ hybridization, <25 cells, each probe set (if appropriate)
88274 – Interphase in situ hybridization, 25 to 99 cells, each probe set (if appropriate)
88275 – Interphase in situ hybridization, 100 to 300 cells, each probe set (if appropriate)